MedTrace Logo

First choIce Antidepressants: General Practitioner's Treatment Approach in the Czech Republic

NCT05291897 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2023-07-18

No results posted yet for this study

Summary

According to the local guidelines (Recommendation for General Practitioners), the first choice Anti-Depressant (AD) in Major Depressive Disorder (MDD) in primary care should be selective serotonin reuptake inhibitors (SSRI), e.g. citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, in depression with anxiety and insomnia is preferable trazodone and in severer disorders mirtazapine. Despite all these molecules have a very good antidepressant effect, there are differences in side effect scale and tolerability.

The aim of this Study is describing of real treatment practice and MDD management in primary care - aimed to evaluate effectiveness of the treatments in depression and related symptoms: insomnia, anxiety, anhedonia and sexual dysfunction.

The primary objective of the Study is to describe the diagnostic process and treatment patterns in MDD- treatment of choice (pharmacologic with details of first choice antidepressant) in the office of GP's.

The secondary objective is to evaluate efficiency of the treatments in depression and related symptoms: insomnia, anxiety, anhedonia and sexual dysfunction and to monitor the type of side effects and comedication during the 8-weeks treatment.

Conditions

  • Major Depressive Disorder Co-Occurrent With Anxiety
  • Adult Patients
  • Newly Diagnosed Depression

Sponsors & Collaborators

  • Institut biostatistiky a analýz, s.r.o. (IBA)

    collaborator UNKNOWN

  • MINDPAX, s.r.o.

    collaborator UNKNOWN

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Angelini Pharma Česká republika s.r.o.

    lead INDUSTRY

Principal Investigators

  • Filip Španiel, MD, PhD · National Institute of Mental Health (NIMH)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-15
Primary Completion
2023-06-10
Completion
2023-06-30

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05291897 on ClinicalTrials.gov